INTRODUCTION
Inherited deficiency of adenosine deaminase (ADA), ' an enzyme of purine salvage, usually results in the syndrome of severe combined immunodeficiency disease (SCID) (1) (2) (3) . Approximately 85% of ADAdeficient infants present with full blown, classic SCID. In these patients, cellular and humoral immune function are both profoundly impaired, their illness begins during the first few months of life, and they succumb rapidly to their multiple infections. Approximately 15% of ADA-deficient infants become ill at a later age and have a more prolonged course, although they too eventually succumb to their disease within the first few years of life. In vitro tests of immune function in these latter patients reveal a more pronounced defect of cellular than of humoral immunity (2, 3) . This clinical heterogeneity could result from either genetic heterogeneity or random differences in exposure to infectious agents. Genetic heterogeneity alone would appear to account for the one clinically healthy, immunologically normal individual who was inadvertently discovered during population studies of the !Kung tribe of the Kalahari Desert (4). This !Kung tribesman lacks ADA in his erythrocytes but his lymphocytes contain appreciable ADA activity (5) . Extensive prior studies of many different populations, directed at determining frequencies of the genetically polymorphic forms of ADA, had not detected any other healthy individual deficient for ADA (6) . As part of the New York State mnandatory screening of newborns, a second individual who totally lacks ADA in his erythro-'Abbreviatiotis used in this paper: ADA, adenosine deaminase; EHNA, erythro-9-(2-hydroxy-3-nonyl-) adenine; LTL, long-term lymphoid RBC, erythrocyte(s); SCID, severe combined immunodeficiency disease.
cytes but who has remained clinically healthy and immunologically normal at 2.5 yr of age (7)2 has been ascertained. We have quantitatively and qualitatively examined ADA activity in this child's erythrocytes and lymphoid cells, both cultured and uncultured. We have compared this child's ADA activity with that found in cells of patients with ADA deficiency and SCID and in cells of the previously reported healthy !Kung tribesman. We have also compared adenosine and deoxyadenosine metabolites in cells and body fluids. The lymphocytes and cultured lymphoid line cells of our patient, similar to the !Kung tribesman, have greater residual activity than do those of other ADA-deficient patients who are immunodeficient, but this adenosine deaminating activity is unstable in vitro, as is the ADA of the !Kung tribesman. However, this ADA activity is sufficient in both our patient and the !Kung tribesman to almost totally prevent the accumulation of substrates of ADA and their potentially toxic metabolites in vivo. Adenoside and deoxyadenosine deaminating activity.
Method 1 ("high substrate"). Adenosine and deoxyadenosine deaminating activity were assayed as previously described (8) by a modification of the method of Hopkinson (9) in which the substrate concentration is approximately four times that originally used. This method measures the increase in absorbance at 293 nm resulting from the conversion of adenosine to inosine by endogenous ADA and then to uric acid by the sequential action of exogenous nucleoside phosphorylase and xanthine oxidase at 37°C. In brief, a reaction mixture was made with 1.3 mM adenosine or deoxyadenosine in 0.05 M Na/PO4 buffer, pH 7.5, 1 ,ug/ml nucleoside phosphorylase, and 50 Zg/ml xanthine oxidase. Aliquots of cell suspension (0.1 ml of a 1:41 dilution of washed erythrocyte(s) (RBC) or from 25 to 500 ,ug of lymphocyte or lymphoid line cell lysate protein) were added per milliliter of reaction mix and the rate of increase in absorbance at 293 nm determined for a linear portion of the curve. The rate of reaction was linear with varying protein concentration for the aliquots used. For assay of RBC the endogenous nucleoside phosphorylase is not rate limiting, and exogenous nucleoside phosphorylase was therefore omitted. The activity of a reagent blank, minus cell extract, was determined simultaneously, to correct for the ADA contaminating the commercial exogenous enzyme preparations.
Method 2 ("low substrate"). To increase the specificity of the ADA assay, enzyme activity was determined at low substrate concentration and as that activity which could be inhibited by 50 jsM EHNA, an inhibitor of ADA. Such assay conditions should eliminate measurement of the activity of a second isozyme of ADA (ADA2) which is present in normal amounts in ADA,--SCID patients, is active at high substrate concentrations, and is not inhibitable by EHNA (10) . Additionally, the assays were performed in tris EDTA buffer to inhibit possible formation of inosine by sequential phosphorylation, deamination, and dephosphorylation of adenosine through alternative pathways. On a kinetic basis alone, enzyme activity determined at 0.09 mM substrate concentration should be 370% of that seen at 1. were determined by electrophoresis in starch gel as described by Spencer et al. (12) . Heat stability. Cell pellets were resuspended in 0.15 M NaCl, 0.05 M Tris, pH 7.5, at a protein concentration of >1 mg/ml, to avoid effects of ionic strength and protein on heat stability (13, 14) . The ADA phenotype of all normal lymphoid cells used In heat stability experiments, unless otherwise noted, was ADA 1, as normal ADA,2-1 is slightly less stable than ADA11 (13, 14) . Equal volumes of cell lysate at equal protein concentrations were incubated for the indicated time intervals at 56°C. After removal to ice, the lysates were appropriately diluted so that assay of the zero time sample would result in =10-30% conversion of the [I4C]adenosine and would be equivalent in the lysates to be compared. Two dilutions were assayed at each time point in the presence and absence of EHNA.
Sephadex G-200 chromatography. Chromatography of cell lysates was performed on 0.6 x 30-cm Sephadex G-200 columns (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) which had been calibrated with nucleoside phosphorylase Adenosine Deaminase Deficiency (89,000), peptidase B (54,000) and ADA (32, 000 (19), Dr. P. Papageorgiou (GM 2825), and from the patient reported here (GM 2294) (7, 15) . Cells from patients of Dr. R. Hong (15) and Dr. C. Griscelli were also studied but long-term lymphoids (LTL) are not available. A series of genetically polymorphic enzyme markers was determined at intervals to confirm the identity of the lines under study.
The clinical and immunological studies of the 2.5-yr-old immunologically normal child studied here have been previously reported (7) Lymphoid cells were suspended in 0.001 M Tris, pH 7.5, at such concentrations that the Tris did not affect the Lowry determinations, frozen and thawed five times, and briefly sonicated. Aliquots were then appropriately diluted for assay.
Deoxij anid adeniosinte kinase. These activities were assayed as described by Carson (20) , except that the final concentration of deoxyadenosine was 0.246 mM, adenosine 103 mM, ATP 4.4 mM, and MgCl2 2.2 mM.
clATP. dATP in RBC was determined by high-pressure liquid chromatography on a Laboratory Data Control System with a variable UV monitor using a Whatman Partisil 10 SAX column (Whatman, Inc., Clifton, N. J.) as described by Cohen (15) and by the more sensitive DNA polymerase assay adapted from Solter et al. (21) . Essentially, 10-,ul aliquots of perchloric acid precipitated, KOH-neutralized extracts were incubated in the presence of saturating concentrations of unlabeled dCTP, dTTP and dGTP, and [U-14C]dCTP (Amersham Corp., Arlington Heights, Ill., 414 mCi/mmol) using a template ofcalf thymus DNA and E. coli DNA polymerase (Worthington Biochemicals). The assay was linear between 25 and 1,000 pmol/10-,ul sample.
Deoxyadenosine and adenosine. Deoxyadenosine and adenosine in urine were determined both with and without prior separation on anion exchange columns (AG 1-X2, BioRad Laboratories, Richmond, Calif.) essentially as described by Kuttesch et al. (22) , and fractions lyophilized. The urinary nucleosides vere separated by high-pressure liquid chromatography on a Waters '8C Bondapak reverse phase column (Waters Associates, Milford, Mass.) by a modification of the method of Brown (23) using a flow rate of 1.5 ml/min and a 30-min linear gradient starting with 10 mM ammonium phosphate buffer, pH 5.5, and ending with 20% methanol in the initial buffer. Adenosine and deoxyadenosine were identified by coelution with standards, 250:260 ratios, and peak shift to the elution volume of inosine and deoxyinosine following incubation with exogenous calf-intestinal ADA.
Separation of RBC on discontinuous density gradients.
Before centrifugation blood was either passed through filter paper or, in later experiments, through a-cellulose-microcrystalline cellulose columns as described by Beutler (24) for removal of leukocytes. RBC of differing densities were then separated by centrifugation on arabinogalactan gradients as described (25) . Gradient (ADA,--SCID) (Table I) . (RBC-ADA activity of both his parents was below 2 SD from the normal.) ADA activity of his mononuclear cells, determined at high substrate concentrations, was 214+43 U (17% of normal) compared with an average of 136+66 U (10% of normal) in mononuclear cells from five ADA,--SCID.
Although average ADA activity in the RBC-ADAhealthy child's mononuclear cells appeared to be slightly higher than in mononuclear cells of the immunodeficient children (214 vs. 136 U), there was overlap of individual values between the two groups and the difference was not significant (P > 0.2). No such overlap was observed upon determination of ADA activity of cultured lymphoid line cells. ADA activity of LTL line cells derived from this patient was markedly greater than that observed in LTL of ADA--SCID patients (590 vs. 13 U). Normal lymphoid line cells contained an average of 2,003 U (range, 1,200-2,700).
The relatively minor difference in ADA activity of peripheral blood mononuclear cells, but marked difference in ADA activity of LTL cells from our ADAhealthy patient, as compared with that of patients with ADA--SCID, led us to further investigate this adenosine deaminating activity. Schrader et al. (10) have described an additional ADA activity in some normal tissues which differs from the major ADA in that it is active only at high substrate concentrations, is not inhibitable by EHNA (an inhibitor of the usual form of ADA), and is found in normal amounts in tissues of an ADA-deficient child. In accordance with isozyme nomenclature we have tentatively denoted the high- (Table I vs. Table II) . In theory, a mutation of the ADA enzyme molecule could affect adenosine deaminating activity relative to deoxyadenosine deaminating activity. Because accumulation of deoxyadenosine compounds appears to be implicated in the pathophysiology (14, 15, 17, 24) we determined deoxyadenosine deaminating activity. The ratio of deoxyadenosine to adenosine deaminating activity was essentially the same in our patient's lymphoid cells as in normals (Table III) . In three ofthe four ADA--SCID patients' cells tested, deoxyadenosine deaminating activity had a ratio of adenosine to deoxyadenosine deaminating activity similar to normal. In the cells of a fourth patient (GM 1715), the ratio of adenosine:deoxyadenosine deaminating activity appeared to be low. However, the absolute activities in these cells were extremely low and would require further investigation. Deoxyadenosine and adenosine phosphorylating activity was also similar in lymphoid cell extracts from normals, ADA--SCID patients, and our partially ADA-patient (data not shown).
Adenosine Deaminase Deficiency therefore determined EHNA-inhibitable activity in RBC of different ages, separated by centrifugation on arabinogalactan gradients (25) . The expected age dependency of the cell fractionation was verified by the progressive decline of pyruvate kinase activity in the gradient fractions (25) . ADA in normal RBC essentially showed no age-dependent decrease in activity (t412 = 231 d) (Fig. 1) . Initial determinations ofADA activity in gradient-separated RBC of an ADA-healthy child revealed a two-component curve of decay with a very short half-life (3.2 d) of the first component (not shown). However, the presence of small but detectable numbers of lymphocytes (containing substantial ADA activity) in the reticulocyte rich fraction could have been responsible for this result. To further reduce lymphocyte contamination we column-purified RBC, lysed them in a buffer in which lymphocytes remained microscopically intact, and assayed the supernate. Determination of ADA activity of such gradient-separated RBC of our ADA-healthy child revealed that all fractions contained < 1% of normal ADA activity (Fig. 1 consistent with the existence of an unstable enzyme with a t112 of 22.5 d (r = 0.751, P = 0.0124). However, because of the greater difference in enzyme content between RBC and lymphocytes of the patient than that of normals, we could not definitively rule out the possibility that undetected contamination of the upper layers of reticulocytes by small numbers of lymphocytes was responsible for the apparent increased activity in these fractions.
We next determined the stability of the enzyme to heating. ADA of normal lymphoid line cells (ADA1 1 phenotype) exhibited a logarithmic decay of enzyme activity at 56°C with a t1/2 of _50 min, as previously reported for ADA, 1 (13) . (Fig. 2) . ADA of the patient's lymphoid line cells was very unstable and had lost 50% of activity in <10 min. ADA activity of lymphocytes from the !Kung tribesman was also unstable with a t1/2 of 10 min. Residual EHNA-inhibitable ADA activity of lymphoid line cells from one ADA1-patient (GM 2606) with SCID showed normal stability (Fig. 2) weight (_32,000 daltons) catalytic unit or combined with an enzymatically inactive subunit of-100,000 mol wt which has varying degrees of glycosylation (26) (27) (28) (29) (30) . The several forms of the enzyme thus contain the same catalytic subunit and are inhibitable by EHNA. In contrast, the ADA2 isozyme has been reported as a 100,000 mol wt species and is essentially not inhibitable by EHNA (10) . Various tissues and fibroblasts can contain both high and low molecular weight forms ofADA, (26, 31) . In contrast, normal LTL, similar to RBC, upon electrophoresis on starch gel and staining, exhibit detectable amounts of only the anodally migrating, low molecular weight form of ADA1. On column chromatography >97% of normal lymphoid line ADA eluted with a molecular weight of -32,000 (Fig. 3) . The remainder of the activity was found as a high molecular weight species which was also inhibitable by EHNA. Under these conditions, EHNA noninhibitable activity is not detected in normal lymphoid line cells. ADA of lymphoid line cells derived from our patient also eluted primarily as a 32,000-mol wt species. About 8% ofthe activity eluted as a high molecular weight species which was also inhibitable by EHNA. ADA of lymphocytes and lymphoid line cells of the !Kung tribesman also demonstrated a major peak of ADA activity at 32,000 daltons. In contrast, chromatography of enzyme activity from lymphoid line cells of an ADA--SCID patient (GM 1715), in which >50% ofADA activity was not EHNA-inhibitable (Table II) , showed only a minor EHNA-inhibitable peak at 32,000 mol wt with the remainder of the ADA activity eluting as high molecular weight activity (>200,000; not shown) which was essentially not inhibitable by EHNA. This ADA activity could represent a dimer of the ADA2 isozyme described by Schrader (22) . Adenosine Deanminase Deficiency The Lineweaver-Burk plot suggests that total residual ADA activity reflects two species of ADA; the Km of 40 ,uM is like that of the normal ADA, isozyme (affected in ADA--SCID), whereas the Km of 330 AM is like that of the normal ADA2 isozyme (10) . Over 90% of the ADA activity determined at high substrate eluted as a non-EHNA inhibitable high molecular weight species, properties which are characteristic of the ADA2 isozyme (not shown). Initially, mononuclear cell ADA activity was determined under conditions which could measure activity ofthe ADA2 isozyme in addition to the activity of ADA1, which is deficient in ADA l-SCID. Under these conditions, our patient's mononuclear cells contained detectably but not strikingly greater ADA activity than did mononuclear cells from patients with ADA,--SCID. In contrast, when assayed under conditions more specific for measurement ofthe major human form of ADA (ADA,), mononuclear cells from ADA1-SCID patients contained very little residual activity (average = 2% of normal) although mononuclear cells of our ADA-healthy patient still exhibited substantial activity (24% of normal). The !Kung tribesman has previously been reported to have 20% of normal lymphocyte ADA activity (5) . The values reported here for ADA activity oflymphocytes from the !Kung tribesman, although higher than mononuclear cell ADA of ADA-SCID, are relatively lower than previously reported. However, the values for the !Kung cells may be factitiously low as both the lymphocytes and RBC were isolated from whole blood in ACD solution which had been in transit for over 4 d and arrived at room temperature.
LTL line cells from both our patient and the !Kung tribesman also exhibited substantial ADA activity, in contrast to lymphoid line cells from patients with ADA--SCID. Lymphoid line cells derived from the !Kung tribesman exhibited activity similar to lymphoid lines from obligate heterozygotes for ADA deficiency and individual values overlapped with those of normal lymphoid line cells. ADA activity in lymphoid line cells from our patient showed marked variation. We have previously reported that ADA activity of normal and deficient fibroblasts shows significant (approximately twofold) variation with differing growth conditions (31) . Such alterations may also occur in lymphoid line cells and be magnified by the presence of an unstable enzyme.
ADA activity in lymphoid cells of both the !Kung tribesman and our patient was markedly less stable in vitro than normal. Because both may share a common racial background, it is tempting to speculate that they carry the same mutations. In addition, an ADA--SCID patient whose lymphoid line ADA suggested a twocomponent heat stability shares the same ethnic background as does the !Kung, our patient, and another patient whose ADA was reported to be less stable when exposed to heat (26) . Determination of the amino acid and base substitutions involved will be required to determine whether these patients do indeed carry the same mutation.
We have also attempted to examine in vivo stability of the ADA by determining activity in RBC of different ages. The results are compatible with a diminished half-life of ADA in vivo. However, because the ratio of activity in lymphocytes to that in RBC is -100:1 in the patient (but only about 10 
